Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
Executive Summary
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.
You may also be interested in...
Oncology Combo Drugs Face UK Market Access Disappointment
New oncology drugs forming new treatment combinations will face a tough ride through England’s influential health technology appraisal body, NICE.
Tagrisso Funding Journey Shows UK’s Revamped Cancer Drugs Fund Is No Soft Touch
AstraZeneca’s Tagrisso is the first product accepted for use on the National Health Service through the reformed Cancer Drugs Fund, but it took two tries to persuade HTA body NICE it should be funded at all. NICE examined Merck Sharp & Dohme’s Keytruda and it’s not impressed. The Pink Sheet takes a closer look at the new dynamics illustrated by these lung cancer treatments’ review.
Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant
Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.